Table 1. Baseline characteristics for WHO₂₀₀₇ cohort (N=421).

Clinical characteristics	No. of patients (%)
	WHO II	WHO III	WHO IV	All
Gender
Male	95 (59.7%)	52 (63.4%)	106 (58.9%)	253 (60.1%)
Female	64 (40.3%)	30 (36.6%)	74 (41.1%)	168 (39.9%)
Age (yrs)
Mean+SD	39±11	39±12	50±12	43±13
Range	16-64	14-72	14-71	14-72
Tumor size (cm)
Mean	4.9±2.0	5.5±1.9	5.5±1.5	5.2±1.8
Range	1.2-11.0	2.0-10.0	2.0-10.0	1.2-11.0
KPS score
Median	90	90	80	90
Range	50-90	30-90	10-90	10-90
N/A	74	31	20	125
Resection
GTR	91 (57.2%)	51 (62.2%)	133 (73.9%)	275 (65.3%)
Non-GTR	68 (42.8%)	31 (37.8%)	47 (26.1%)	146 (34.7%)
Chemotherapy
Yes	59 (37.1%)	56 (68.3%)	152 (84.4%)	267 (63.4%)
No	87 (54.7%)	16 (19.5%)	21 (11.7%)	124 (29.5%)
N/A	13 (8.2%)	10 (12.2%)	7 (3.9%)	30 (7.1%)
Radiotherapy
Yes	77 (48.4%)	59 (72.0%)	162 (90.0%)	298 (70.8%)
No	69 (43.4%)	12 (14.6%)	9 (5.0%)	90 (21.4%)
N/A	13 (8.2%)	11 (13.4%)	9 (5.0%)	33 (7.8%)
1q/19p polysomy
1q single polysomy	5 (3.1%)	4 (4.9%)	9 (5.0%)	18 (4.3%)
19p single polysomy	4 (2.5%)	9 (10.9%)	27 (15.0%)	40 (9.5%)
Co-polysomy	33 (20.8%)	24 (29.3%)	28 (15.6%)	85 (20.2%)
No polysomy	117 (73.6%)	45 (54.9%)	116 (64.4%)	278 (66.0%)
IDH1/2 mutation
Yes	65 (40.9%)	30 (36.6%)	31 (17.2%)	126 (29.9%)
No	53 (33.3%)	39 (47.6%)	111 (61.7%)	203 (48.2%)
N/A	41 (25.8%)	13 (15.9%)	38 (21.1%)	92 (21.9%)
Follow-up
Progression	62/155 (40.0%)	44/77 (57.1%)	137/173 (79.2%)	243/405* (60.0%)
Mean PFS (mos)	48.0 (95%CI 34.9-61.1)	21.0 (95%CI 13.5-28.6)	10.0 (95%CI 8.5-11.5)	19.5 (95%CI 15.7-23.3)
Dead	32/155 (20.6%)	29/78 (37.2%)	103/180 (57.2%)	164/413* (39.7%)
Mean OS (mos)	N/A	30.0 (95%CI 20.2-39.7)	21.5 (95%CI 17.5-25.5)	45.0 (95%CI 33.6-56.4)

* PFS was not available in 16 cases and OS was not available in 8 cases. N/A= not available. GTR=gross-total resection.